As Court Battle Rages, Pfizer's Celebrex Sales Soar
In its annual financial statement to the U.S. Securities and Exchange Commission, drug maker Pfizer Inc. warned that "continuing concern" about the safety of its anti-inflammatory drug Celebrex might limit the...To view the full article, register now.
Already a subscriber? Click here to view full article